Ken Griffin Jazz Pharmaceuticals PLC Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$115.19 - $132.77 $2.36 Million - $2.72 Million	-20,500 Reduced 50.0%	20,500 $2.47 Million
Q4 2023 Feb 14, 2024	BUY	$114.26 - $136.0 $1.37 Million - $1.63 Million	12,000 Added 41.38%	41,000 $5.04 Million
Q3 2023 Nov 14, 2023	BUY	$122.0 - $145.31 $244,000 - $290,620	2,000 Added 7.41%	29,000 $3.75 Million
Q2 2023 Aug 14, 2023	BUY	$122.5 - $147.16 $710,500 - $853,528	5,800 Added 27.36%	27,000 $3.35 Million
Q1 2023 May 15, 2023	SELL	$133.98 - $160.47 $349,955 - $419,147	-2,612 Reduced 10.97%	21,200 $3.1 Million

Q4 2022 Feb 14, 2023	SELL	$129.72 - $159.85 $10.2 Million - $12.5 Million	-78,500 Reduced 76.73%	23,812 $3.79 Million
Q3 2022 Nov 14, 2022	BUY	$126.59 - $161.18 $10.5 Million - $13.3 Million	82,812 Added 424.68%	102,312 $13.6 Million

513

57M

65.9K

183K

Ticker JAZZ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,680,700
Market Cap $6.49B
Description
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.